Following its recent acquisition announcement, Sage Therapeutics plans to lay off nearly all employees, with state filings detailing a reduction of 338 jobs effective August 22. This move follows Sage’s reported employment of 353 staff earlier in 2025 and coincides with integration plans under Maryland-based Supernus Pharmaceuticals, who acquired the company in a deal valued up to $795 million. The workforce reduction reflects strategic restructuring post-merger.